Inclusion Criteria:~1. Diagnosis of prodromal AD, including the following:~ 1. History of subjective memory
decline with gradual onset and slow progression for at least one year corroborated by an informant,~ 2.
Objective impairment in episodic memory by memory test performed at Screening,~ 3. Does not meet criteria for
dementia, AND~ 4. Positive Screening amyloid imaging PET scan using \[18F\]flutametamol tracer or positive
Screening CSF tau:amyloid-Î²42 (AÎ²42) ratio (Participants with a prior positive amyloid imaging PET scan or a
Screening PET scan with florbetaben or florbetapir may be enrolled without a Screening flutemetamol scan with
Sponsor approval)~2. Able to read at a 6th grade level or equivalent~3. If participant is receiving an
acetylcholinesterase inhibitor or memantine, the dose must have been stable for at least three months before
Screening~4. Must have a reliable and competent trial partner/informant who has a close relationship with the
participant and is willing to accompany the participant to all required trial visits, and to monitor compliance
of the administration of the trial medication~Inclusion Criteria for Extension Period (Part 2):~1. Tolerated
study drug and completed the initial 104-week period of the trial (Part 1)~2. Participant must have a reliable
and competent trial partner who must have a close relationship with the subject~
